UK markets close in 8 hours 9 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0300+0.0499 (+5.09%)
At close: 04:00PM EST
1.0202 -0.01 (-0.95%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.9801
Open0.9900
Bid0.0000 x 2200
Ask0.0000 x 1200
Day's range0.9637 - 1.0300
52-week range0.5900 - 1.3900
Volume503,048
Avg. volume427,435
Market cap129.063M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-0.2400
Earnings date20 Mar 2024 - 25 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.58
  • GlobeNewswire

    Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

    SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R

  • GlobeNewswire

    Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

    SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that the (Z)-endoxifen arm of the ongoing Phase 2 I-SPY 2 clinical trial has fully enrolled. In the study, (Z)-endoxifen, Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), is being evaluated as a neoadjuvant treatment for

  • Simply Wall St.

    Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?

    We feel now is a pretty good time to analyse Atossa Therapeutics, Inc.'s ( NASDAQ:ATOS ) business as it appears the...